A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Phase 2

Completed

• Conditions: Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
• Interventions: Drug: Ramucirumab

• Registration Number: NCT02443883
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The main purpose of this study was to evaluate the safety and pharmacokinetics of administering various dose regimens of ramucirumab in participants with advanced gastric cancer whose disease has progressed during or following prior chemotherapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-05-12
• Study First Submitted QC: 2015-05-12
• Study First Posted: 2015-05-14
• Study Start: 2015-07-07
• Primary Completion: 2016-11-18
• Results First Submitted: 2017-10-28
• Results First Submitted QC: 2018-03-02
• Results First Posted: 2018-03-13
• Study Completion: 2019-06-05
• Status Verified: 2019-07
• Last Update Submitted: 2020-06-26
• Last Update Posted: 2020-06-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 164

Inclusion Criteria

• The participant has a histopathologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction (GEJ).

• The participant has documented disease progression during or within 4 months after the last dose of first-line chemotherapy for metastatic disease, or during or within 6 months after the last dose of neoadjuvant or adjuvant therapy.

• The participant received combination chemotherapy prior to disease progression.

  • Prior chemotherapy regimens must include a platinum and/or a fluoropyrimidine component and must not include a taxane or antiangiogenic agent.

• The participant has metastatic disease or locally advanced disease that is measurable or nonmeasurable, but is evaluable disease by radiological imaging per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).

• Patients are eligible if they are considered not appropriate, for whatever reason, for treatment with ramucirumab in combination with paclitaxel.

• The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• The participant has adequate organ function, including:

  • Total bilirubin 1.5 × the upper limit of institutional normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 × ULN. If the liver has tumor involvement, AST and ALT <5 × ULN are acceptable.
  • Serum creatinine 1.5 × ULN or calculated creatinine clearance (per the Cockcroft-Gault formula or equivalent and/or 24-hour urine collection) 60 milliliters/minute (mL/min).
  • Urinary protein is <2+ on dipstick or routine urinalysis.
  • Absolute neutrophil count 1.5 × 10^9/Liter (L), platelets 100 × 10^9/L, and hemoglobin 9 g/deciliter (dL) (5.58 millimoles/Liter).
  • International normalized ratio 1.5 × ULN or prothrombin time 5 seconds above ULN.
  • Partial thromboplastin time 5 seconds above ULN.

• The participant has an estimated life expectancy of 12 weeks in the judgment of the investigator.

• The participant, if female and of child-bearing potential, must have a negative serum or urine pregnancy test within 7 days prior to randomization.

Exclusion Criteria

• The participant has squamous cell or undifferentiated gastric cancer.

• The participant is receiving chronic therapy with any of the following within 7 days prior to randomization:

  • Nonsteroidal anti-inflammatory agents (NSAIDs; such as indomethacin, ibuprofen, naproxen, or similar agents), or
  • Other anti-platelet agents (such as clopidogrel, ticlopidine, dipyridamole, or anagrelide). Aspirin use at doses up to 325 milligrams (mg)/day is permitted.

• The participant received radiotherapy within 14 days prior to randomization.

• The participant received >1 line of prior therapy for the treatment of locally advanced and unresectable or metastatic gastric or GEJ (Siewert Types I-III) adenocarcinoma.

• The participant received previous treatment with agents targeting the vascular endothelial growth factor (VEGF)/VEGF receptor 2 signaling pathway.

• The participant has documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression.

• The participant experienced any arterial thromboembolic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to randomization.

• The participant has symptomatic congestive heart failure (New York Heart Association II-IV) or symptomatic or poorly controlled cardiac arrhythmia.

• The participant has uncontrolled hypertension, as defined in Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, prior to initiating study treatment, despite antihypertensive intervention.

• The participant underwent major surgery within 28 days prior to randomization or central venous access device placement within 7 days prior to randomization.

• The participant has a history of gastrointestinal perforation or fistula within 6 months prior to randomization.

• The participant has any condition (for example, psychological, geographical, or medical) that does not permit compliance with the study and follow-up procedures or suggests that the participant is, in the investigator's opinion, not an appropriate candidate for the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ramucirumab Regimen 4	Ramucirumab	Experimental dose of 8 mg/kg ramucirumab given IV on day 1 and day 8 of each cycle (21-day cycle) until discontinuation criteria are met.
Ramucirumab Regimen 2	Ramucirumab	Experimental dose of 12 mg/kg ramucirumab given IV on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
Ramucirumab Regimen 1	Ramucirumab	Standard dose of 8 milligram per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
Ramucirumab Regimen 3	Ramucirumab	Experimental dose of 6 mg/kg ramucirumab given IV on day 1, 8, 15 and 22 of each cycle (28-day cycle) until discontinuation criteria are met.

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab	Day 29, 43, 71 and 85: predose	The Cmin is the minimum observed serum concentration of ramucirumab.

Secondary Outcome Measures

Name	Time	Method
Immunogenicity: Number of Participants With Anti-Ramucirumab Antibodies	Predose Cycle 1 Through Short Term Follow Up (Up to 5 Months)	Number of participants with positive treatment emergent anti-ramucirumab antibodies was summarized by treatment group. A treatment-emergent anti-drug antibodies (TEADA) sample was defined as: a post treatment sample with at least a 4-fold increase in titer from pre treatment sample; or 1:20 post treatment titer for participants that had no detectable ADA titer at baseline.
Rate of Progression Free Survival (PFS) at the First 6-Week Tumor Assessment	Baseline until the first 6-week tumor assessment	PFS defined as the time from first day of therapy to first evidence of disease progression per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) or death from any cause up to the first 6-week tumor assessment. Progressive Disease (PD) is at least 20% increase in sum of diameters of target lesions,taking as reference smallest sum on study and absolute increase of at least 5 mm.Appearance of 1 or more new lesions was also considered progression. Nontarget PD is unequivocal progression of existing nontarget lesions.Appearance of 1 or more new nontarget lesions was also considered PD.Participants with no baseline disease assessment: PFS time was censored at the randomization date,regardless of whether or not objectively determined disease progression or death has been observed.

Trial Locations

Locations (9)

USC Norris Cancer Hospital; 🇺🇸 Los Angeles, California, United States

Carolinas Medical Center; 🇺🇸 Charlotte, North Carolina, United States

Arizona Clinical Research Center; 🇺🇸 Tucson, Arizona, United States

Oklahoma Cancer Specialists & Research Institute, LLC; 🇺🇸 Tulsa, Oklahoma, United States

University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

Arkhangelsk Regional Clinical Oncology Dispensary; 🇷🇺 Arkhangelsk, Russian Federation

Leningrad regional clinical hospital; 🇷🇺 St. Petersburg, Russian Federation

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician; 🇸🇰 Kosice, Slovakia

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.; 🇬🇧 Wolverhampton, United Kingdom